|Bid||115.25 x 800|
|Ask||119.59 x 800|
|Day's Range||117.14 - 119.46|
|52 Week Range||113.36 - 136.83|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year.Source: Shutterstock
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
VanEck announced today the following 2017 annual distributions per share for its VanEck Vectors® equity exchange-traded funds.
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.
Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank #1, 2 or 3 would lead to profits in investor portfolios.
Allergan (AGN) is a US-based pharmaceuticals company that deals in over-the-counter products, eye care products, and aesthetics products.
Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: ...
Todd Hagopian’s Biotech Fund is up over 30% as many of his stock picks have taken off after President Trump and Senate Republicans turned their attention to healthcare.
Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.
Mark Alles, Celgene CEO, talks about the importance of forming a partnership between innovators and insurance companies in order to provide patients with access to precision medicines.
Mark Alles, Celgene CEO, talks about gaining FDA approval for a drug that targets a lethal form of leukemia and discusses the importance of getting patients access to precision medicines.